Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00065130 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes
A Phase 3 study of Diabetes and Gestational Diabetes, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT00065130 is a Phase 3 study of Diabetes and Gestational Diabetes that has completed, run by Novo Nordisk A/S. The registered enrollment target is 27 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00065130, a Phase 3 study of Diabetes and Gestational Diabetes, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial is conducted in the United States of America (USA). The purpose of this study is to test whether NovoLog (insulin aspart) is a safe and at least as effective alternative to regular human insulin for the control of blood glucose after meals in women who develop diabetes during pregnancy.
Conditions Studied
Interventions
- DRUG insulin aspart
- DRUG insulin NPH
- DRUG human insulin
Study Locations (1)
California
- Novo Nordisk Investigational Site - Santa Barbara
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2000-04 |
| Est. Completion | 2003-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00065130
The ClinicalTrials.gov registry entry for NCT00065130 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 3 interventions - of which insulin aspart is the first listed.
NCT00065130 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00065130 about?
NCT00065130 is a clinical study titled "Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes". This trial is conducted in the United States of America (USA). The purpose of this study is to test whether NovoLog (insulin aspart) is a safe and at least as effective alternative to regular human insulin for the control of blood glucose after meals in women who develop diabetes during pregnancy.
What is the current status of trial NCT00065130?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2000-04. Estimated completion is 2003-12.
What conditions does trial NCT00065130 study?
This clinical trial studies the following conditions: Diabetes, Gestational Diabetes.
What interventions are being tested in trial NCT00065130?
The interventions under investigation include: insulin aspart (DRUG), insulin NPH (DRUG), human insulin (DRUG).
Who is sponsoring clinical trial NCT00065130?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00065130 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial to Assess Chelation Therapy in Critical Limb Ischemia
RECRUITING · Phase 3
-
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
ACTIVE NOT RECRUITING · Phase 3
-
Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes
COMPLETED · Phase 3
-
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
COMPLETED · Phase 3
-
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
COMPLETED · Phase 3
-
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.